|
|
Vaccine Detail
|
PSA-OP Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: PSA-OP Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007151
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KLK3
gene engineering:
- Preparation: PSA 30-mer oligoepitope peptide containing motifs for HLA class I-A2, -A3, -A11, and B53 alleles was synthesized on a peptide synthesizer (Correale et al., 1998).
- Description: This is for Prostate Cancer .A 30-residue prostate specific antigen (PSA) oligoepitope peptide (OP) vaccine with potential antineoplastic activity. PSA-OP peptide vaccine contains the PSA-1 and PSA-3 HLA-A2 epitopes and the PSA-9 HLA-class I-A3 epitope joined by peptide linker sequences. In an animal model, vaccination with this agent has been shown to elicit a cytotoxic T-lymphocyte immune response (Correale et al., 1998; NCIT_C29337).
|
| Host Response |
|
|
| References |
Correale et al., 1998: Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(6); 3186-3194. [PubMed: 9743387].
NCIT_C29337: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29337]
|
|
